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Abstract 
Background: Short Message Service (SMS) reminders have been suggested as a potential intervention for improving 
adherence to medications and health facility attendance.
Methods: An open-label, randomized, controlled trial to test the efficacy of automated SMS reminders in improving 
adherence to artemether–lumefantrine (AL) and post-treatment attendance in comparison with standard care was 
conducted at four health facilities in western Kenya. Children below five years of age with uncomplicated malaria 
were randomized to intervention (SMS reminders) or control groups. Within each study group they were further 
randomized to three categories, which determined the timing of home visits to measure adherence to complete AL 
course and to individual AL doses. A sub-set of caregivers was advised to return to the facility on day 3 and all were 
advised to return after 28 days. The primary outcomes were adherence to medication and return on day 3. The pri-
mary analysis was by intention-to-treat.
Results: Between 9 June, 2014 and 26 February, 2016, 1677 children were enrolled. Of 562 children visited at home 
on day 3, all AL doses were completed for 97.6% (282/289) of children in the control and 97.8% (267/273) in the inter-
vention group (OR = 1.10; 95% CI = 0.37–3.33; p = 0.860). When correct timing in taking each dose was considered 
a criteria for adherence, 72.3% (209/289) were adherent in the control and 69.2% (189/273) in the intervention group 
(OR = 0.82; 95% CI = 0.56–1.19; p = 0.302). Sending SMS reminders significantly increased odds of children return-
ing to the facility on day 3 (81.4 vs 74.0%; OR = 1.55; 95% CI = 1.15–2.08; p = 0.004) and on day 28 (63.4 vs 52.5%; 
OR = 1.58; 95% CI = 1.30–1.92; p < 0.001).
Conclusions: In this efficacy trial, SMS reminders increased post-treatment return to the health facility, but had no 
effect on AL adherence which was high in both control and intervention groups. Further effectiveness studies under 
the real world conditions are needed to determine the optimum role of SMS reminders.
Trial registration ISRCTN39512726
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Background
The expansion of network coverage and mobile phone 
penetration in Africa [1] has offered opportunities to 
improve health communication and support medical 
and public health practice [2]. Text messaging or Short 
Message Service (SMS), the widely used mobile phone 
function, has recently been deployed in numerous health 
projects across Africa [3]. Trials across the continent 
have shown that SMS reminders sent to patients’ mobile 
phones can improve adherence to antiretroviral therapy 
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[4, 5], immunization coverage [6], blood pressure con-
trol [7], emotional outcomes after abortion [8], as well 
as antenatal [9], delivery [10], postpartum [11], postop-
erative [12], and repeat HIV test [13] attendance. Con-
versely, in other trials, SMS reminders were not effective 
in improving adherence to antiretroviral therapy or vol-
untary male circumcision [14, 15].
Most SMS interventions in Africa have been assessed 
in the management of chronic diseases and long-term 
therapy, while their effects on the management of acute 
diseases, such as malaria, have been less commonly inves-
tigated [16]. SMS reminders sent to either health workers 
or malaria patients and their caregivers have been sug-
gested as a potential intervention [16–18] to improve 
sub-optimal caregivers’ adherence to artemisinin-based 
combination therapy (ACT) [19, 20] and poor outpatient 
attendance rates for follow-up [21]. No previous study 
has examined the efficacy of SMS reminders to enhance 
patients’ return to the health facility following malaria 
treatment. Two trials, showing discrepant results, tested 
effects of SMS reminders on patients’ adherence to ACT 
[22, 23].
Non-adherence to anti-malarial medicines and lack 
of patients’ follow-up compromises malaria case man-
agement and favours the emergence of anti-malarial 
resistance [24, 25]. The latter is becoming increasingly 
important with the risk of artemisinin resistance spread-
ing from Southeast Asia to sub-Saharan Africa [26–28]. 
Early warnings of the emergence of resistance may be 
detected by post-treatment monitoring of the outcomes 
of ACT treatment [29, 30]. However, such post-treat-
ment monitoring is only possible if patients return to the 
health facility when requested.
A randomized controlled trial was therefore under-
taken in Kenya to assess whether SMS reminders sent 
to caregivers of children treated with nationally recom-
mended ACT, artemether–lumefantrine (AL), would 
enhance adherence to AL therapy and would increase the 
rates of post-treatment return to the health facility fol-
lowing completion of treatment.
Methods
Study area
The trial was conducted at four public health facilities 
in Siaya County in western Kenya. Two trial sites are 
located in Bondo Sub-county (Bondo and Got Agulu 
Hospitals) and two in Rarieda Sub-county (Ndori Health 
Centre and Madiany Hospital). Malaria transmission in 
the study area is high with seasonal peaks in May–July 
and October–November [31]. AL has been routinely 
used since 2006 as the first-line treatment for uncom-
plicated malaria. Reports of children completing AL 
course ranged from 58–81% [32, 33]. A feasibility study 
undertaken prior to the trial found that the mobile net-
work coverage in the study area was nearly universal with 
over 90% of caregivers of children with malaria having 
access to mobile phones and expressing willingness to 
receive SMS reminders about drug administration and 
when to return to the health facility [34].
Study design
The study was an open-label, randomized, controlled 
trial testing the additional effects of SMS reminders on 
patients’ adherence to AL and their return to the health 
facility compared to the control group receiving stand-
ard care only. This was an efficacy trial where all chil-
dren with uncomplicated malaria received care by study 
personnel in line with national guidelines [35], and with 
additional advice to return to the facility on day 3 and day 
28 post-treatment, to facilitate resistance surveillance. 
Participants were randomized either to the intervention 
(SMS reminders) or to control groups. As a second ran-
domization within each study group, they were further 
randomly assigned to three different categories, which 
determined the timing of home visits to measure adher-
ence (Fig. 1). The categories to determine timing of these 
visits were: category 1: caregivers were visited at home on 
day 1 to measure adherence of the second and the third 
AL dose; category 2: caregivers were visited on day 2 to 
measure adherence of AL doses 4 and 5; and, category 3: 
caregivers were visited at home on day 3 after they had 
completed the full treatment to measure adherence to the 
complete course of AL (doses 2–6) and adherence to the 
individual dose 6. These home visits were used to mitigate 
the anticipated recall bias for measurements of timely 
adherence to individual AL doses [36]. Furthermore, car-
egivers in categories 1 and 2 were advised to return to the 
facility on day 3 and all caregivers were advised to return 
to the facility on day 28. Outcomes were compared across 
randomization groups (i.e., intervention vs control) and 
were assessed within applicable categories as follows: the 
primary outcomes were: (a) the proportion of patients 
adhering to complete AL course (measured among cat-
egory 3); and, (b) the proportion of patients’ returning to 
the facility on day 3 (measured among categories 1 and 
2 combined). The secondary outcomes were (a) adher-
ences to five individual AL doses (measured among all 3 
categories); and, (b) patients’ return to the facility on day 
28 (measured among all 3 categories).
Enrolment
All children suspected of malaria were screened by study 
clinicians at outpatient departments in the study sites 
and enrolled into the trial if they met all of the following 
inclusion criteria: age six to 59 months; weight 5 kg and 
above; history of fever in the previous 24 h or presence 
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of axillary temperature  ≥37.5  °C; microscopically con-
firmed infection of Plasmodium falciparum with parasi-
taemia between 500 and 200,000/μL; caregiver access to 
personal or shared mobile phone within household; car-
egiver ability to open and read SMS either themselves or 
through another person in the household; and, caregiver 
8,600 children screened 
Outpatients with suspected malaria
849 control arm 
• Standard of care
• No SMS reminders
828 intervention arm 







Day 1 adherence measurement of 
AL doses 2 and 3
Day 2 adherence measurement of 
AL doses 4 and 5
Day 3 adherence measurement of AL 
doses 2 to 6 
Primary outcomes
• Adherence to complete AL course (doses 2 to 6 in category 
3)
• Day 3 return to health facility (category 1 and 2 combined)
Secondary outcomes
• Adherence to individual AL doses 2 and 3 (category 1)
• Adherence to individual AL doses 4 and 5 (category 2)
• Adherence to individual AL dose 6 (category 3)
1,677 enrolled and randomized
Outcomes 
6,923 screen failures 
5,387 malaria test negative results
1,335 no phone access or unable to read SMS
788 unwilling to follow study protocol
429 previous participation in the trial
225 with danger/severe malaria signs
208 parasite density <500/µl 
179 no fever history or temperature ≥37.5 °C
109 parasite density >200,000/µl 
















Category 1 and 2 combined (N=516)
516 ITT analysed for Day 3 return 
Category 1, 2 and 3 combined (N=828)
828 ITT analysed for Day 28 return
Category 1 and 2 combined (N=516)
516 ITT analysed for Day 3 return 
Category 1, 2 and 3 combined (N=849)
849 ITT analysed for Day 28 return
Day 3 and Day 28 return to 
health facility 
Fig. 1 Trial profile
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provision of written informed consent. The following 
exclusion criteria applied: presence of clinical danger 
signs, severe anaemia [haemoglobin (Hb) <5 g/dl] or any 
other severe malaria criteria; severe malnutrition (weight 
for height  <70%); ongoing prophylaxis with drugs hav-
ing anti-malarial activity such as cotrimoxazole; reported 
hypersensitivity to AL; presence of any concurrent ill-
ness; and, previous participation in the trial. Thick and 
thin blood smears were performed by the study micros-
copists, who counted asexual parasites per 200 white 
blood cells (WBCs) and calculated parasite density on the 
estimate of 8000 WBCs/μL. A blood smear was deemed 
negative only after examining 100 high-power micro-
scopic fields. Hb levels were estimated using HemoCue.
Randomizations and masking
The randomization codes were generated by an offsite 
statistician and randomization numbers were applied in 
sequence of recruitment. The trial was open-label. Par-
ticipants and nurses performing home visits could not 
be masked. The study personnel at health facilities were 
necessarily aware of categories for assigning day of home 
visits, but were blind to the intervention arm.
Anti‑malarial treatment
In both arms children were treated with dispersible AL. 
The first dose was supervised at the health facility by a 
study nurse, and repeated if the child vomited within 
30 min. The remaining five doses were taken at home. All 
caregivers received verbal instructions to give the second 
dose exactly 8 h after the first dose with the subsequent 
four doses given on the following 2 days at 08.00 in the 
morning and in the evening at 20.00, and illustrations 
on the AL blister packs that were taken home were used 
to support the explanations. Children weighing 5–14 kg 
were to take single tablet per dose while those weigh-
ing 15–24  kg two tablets per dose. The caregivers were 
advised to administer AL after a meal or with food, to 
complete all doses even if the child appeared better, and 
to return to the health facility immediately if the child’s 
condition worsened.
Intervention—SMS reminders
In total 11 text messages were used where content, tim-
ing, understanding, and distribution had undergone 
extensive pre-testing with community members, caregiv-
ers and patients at four facilities within the same county 
but outside of the study area [37]. Caregivers in the inter-
vention arm were sent automated SMS reminders, timed 
to start 8 h after the first AL dose and then every morn-
ing (08.00) and evening (20.00) until the full AL course 
was administered. For each post-treatment visit (i.e., on 
day 3 and day 28), two SMS reminders were sent, one in 
the evening prior to the day of the appointment and one 
in the morning on the day of the facility visit. Participants 
in category 3 were not sent the day-3 SMS reminder to 
come back to the facility because they would be visited 
on the same day at home. Three messages sent on days 
7, 14 and 21 reminded caregivers about ‘unscheduled’ 
visits if child does not get better. The messages were sent 
in English, Kiswahili or Dholuo depending on caregivers’ 
language preferences. Table 1 shows the final content and 
delivery schedule of all text messages deployed.
Follow‑up
During recruitment, caregivers were informed that they 
would be visited at home but not informed of the spe-
cific day of the visit. They were advised to keep AL blister 
Table 1 Content and schedule of SMS reminders
a Day 3 post-treatment reminders are not sent to the patients in category 3 since they are visited at home
Message category Timing Day of sending Message content
AL dose 2 8 h after first dose Day 0 Hello [name of care giver], have you remembered to give your child 
the [dose number] dose of malaria medicine? If not, please do so. 
Thank you, [Name of HF]
AL dose 3 08:00 Day 1
AL dose 4 20:00 Day 1
AL dose 5 08:00 Day 2
AL dose 6 20:00 Day 2
Day 3 health facility post-treatment visita 20.30 Day 2 Hello [name of care giver], please remember to bring the child back 
to hospital [tomorrow on day 2/today on day 3] to confirm clear-
ance of malaria parasites. Thank you, [Name of HF]
08:00 Day 3
Unscheduled visit 08:00 Day 7 Hello [name of care giver] I hope the child is doing well. If not, please 




Day 28 health facility post-treatment visit 18.30 Day 27 Hello [name of care giver], please bring your child back to the 
hospital [tomorrow on day 27/today on day 28] for day 28 post-
treatment as advised by the doctor. Thank you, [Name of HF]
08:00 Day 28
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packs after completing the treatment course. Home visits 
were undertaken by a study nurse within 24 h of expected 
completion of the individual doses of interest (doses 2 
and 3 in category 1, doses 4 and 5 in category 2, and dose 
6 in category 3). During the home visits, adherence to 
AL was assessed using pill counts and caregivers’ reports 
to determine the number of pills taken prior to the visit 
and the timing of each dose. Caregivers were also asked 
whether they had received text message reminders. 
Caregivers who returned to the health facility on day 3 
(category 1 and 2) were not financially compensated for 
transport costs as this was considered routine, however 
those who returned to the facility on day 28 received 
travel compensation of approximately 2 USD.
Outcomes and definitions
Two primary outcomes were investigated in the trial. 
The first outcome was the proportion of patients adher-
ing to the complete AL course (doses 2–6) measured in 
category 3 using the combination of pill count and self-
reporting. The definition of correct AL adherence was 
based on two criteria of which both had to be met: (1) 
completion of all doses; and, (2) correct timing of all 
doses. To assess completion of all doses the evidence of 
empty AL blister pack during the home visit was used. 
In the absence of blister packs, caregivers’ reports were 
used. To assess timing, caregivers’ report of administered 
doses, within ±1  h for dose 2 and ±2  h for doses 3–6, 
compared to the instructions given at the time of recruit-
ment, was classified as correct. The second primary 
outcome was the proportion of patients in combined cat-
egories 1 and 2 who returned to the health facility on day 
3 after expected completion of AL treatment.
Two secondary outcomes were also investigated in the 
trial. The first secondary outcome was the proportion 
of patients adhering to the individual AL doses meas-
ured within 24  h of expected dose administrations, i.e., 
for doses 2 and 3 in category 1, doses 4 and 5 in category 
2, and for dose 6 in category 3. The adherence defini-
tions for these patient groups followed the criteria of 
dose completion based on appropriate number of tablets 
found at the time of the visit and correct timing, using 
the same time allowances as described for the primary 
outcome. Finally, the last trial outcome was the propor-
tion of patients across all categories that returned to the 
health facility on day 28.
Sample size calculation
The sample size estimation was based on the first pri-
mary outcome (i.e., adherence to the full course of AL 
treatment in category 3) [38]. Assuming adherence of 
65% in the control group, effect size of 10%, 15% loss to 
follow-up, 80% power and 0.05 level of significance, the 
estimated sample size was 400 participants per arm. 
In addition, 300 participants per arm were included in 
each of the first and second categories. These sample 
sizes were estimated to be sufficient to detect an effect 
size of 10% for an estimated individual AL dose adher-
ence at 75% in the control group, assuming a 10% loss to 
follow-up and the same power assumptions. Finally, for 
the measurement of the day 3 return to health facilities, 
the combined sample size in categories 1 and 2 (600 per 
arm), had more than 90% power to detect a 10% differ-
ence from an estimate for the control group of 45% of 
patients returning on day 3. Due to slower recruitment 
than expected and on advice from the Trial Steering 
Committee, an interim analysis was conducted on the 
primary adherence outcome in category 3. The interim 
analysis found  ~70% adherence in the control group, 
higher than the 65% initially estimated, and only 10% 
rather than 15% loss to follow-up. The sample size was 
therefore recalculated using other assumptions as above 
and the recruitment was terminated when 645 patients in 
category 3 and 1677 in total were enrolled.
Analysis
The primary analytic approach was intention-to-treat 
(ITT) including all randomized patients with available 
outcome data. The secondary analytic approach was 
per-protocol (PP) where adherence analyses excluded 
patients who were inadvertently recruited without meet-
ing enrolment criteria and those who did not receive 
SMS reminders in the intervention group. SMS exposure 
was classified on the basis of a caregiver’s report regard-
ing delivery of any SMS reminder.
To estimate effects of the intervention on outcomes, 
mixed effects logistic regression models, with interven-
tion arm as an independent variable adjusted for cluster-
ing by site, was used. The effect was expressed as an odds 
ratio (OR) with corresponding 95% confidence interval 
and p value. Participants’ characteristics were tabulated 
by randomization group. To further assess potential con-
founders, multivariable regression was performed by 
examining each potential confounder as an independent 
variable with randomization group and retaining any of 
the covariates, which changed the unadjusted OR of ran-
domization group by more than 5%.
All trial data were double entered, verified and cleaned 
in Access 2013 (Microsoft Corporation, Seattle, WA), 




Between 9 June, 2014 and 26 February, 2016, 8600 chil-
dren presenting with suspected malaria were screened, 
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of whom 1677 children were enrolled into the trial. The 
most common reasons for screen failures were 5387 
(78.6%) malaria test-negative patients, 1335 (19.3%) with-
out access to SMS messages, and 788 (11.4%) unwilling 
to comply with study protocol over 28  days (Fig.  1). Of 
the 1677 enrolled children, 849 (50.6%) were randomized 
into the control group and 829 (49.4%) into the inter-
vention group. Analyses of the post-treatment return 
included all of the 1677 enrolled children, and for adher-
ence measurements excluded 118 (7.0%) patients who 
were not found at home during the scheduled visits and 
54 patients (3.7%) where visits were made but data on 
adherence were missing. The characteristics of the study 
population were similar between control and interven-
tion groups among all enrolled patients overall and 
within categories (Table 2).
Adherence to complete AL course
Adherence to complete AL course was measured among 
562 patients in category 3 (i.e., having home visits on day 
3, Table 3); 92.4% of caregivers in the control group and 
92.3% in the intervention group kept AL blister packs. 
The ITT analysis showed that 97.7% of patients com-
pleted all AL doses: 97.6% (282/289) in the control and 
97.8% (267/273) in the intervention group (OR  =  1.10; 
95% CI =  0.37–3.33; p =  0.860). When defining adher-
ence as completion of all doses and correct timing of 
all doses, 70.8% of the caregivers adhered to AL treat-
ment schedule; 72.3% (209/289) in the control and 69.2% 
(189/273) in the intervention group (OR  =  0.82; 95% 
CI = 0.56–1.19; p = 0.302). Adherence to individual AL 
doses in category 3 was high for all doses: 76.0% for dose 
2; 96.3% for dose 3; 94.8% for dose 4; 95.6% for dose 5; 
and 89.9% for dose 6. No significant effect of the inter-
vention on any of the five individual doses was observed 
(Table  3). PP analysis after excluding 62 patients who 
reported not receiving SMS in the intervention group 
and 14 protocol violations showed very similar results to 
the ITT analysis: 97.5% of patients completed all doses; 
71.6% of the caregivers adhered to AL treatment sched-
ule: 72.1% (204/283) in the control and 70.9% (144/203) 
in the intervention group (OR =  0.92; 95% CI =  0.61–
1.38; p = 0.690), and without significant effects on any of 
the individual doses (Additional file 1).
Adherence to individual AL doses
Adherence to individual AL doses was measured in each 
of three categories of patients during home visits tak-
ing place within 24 h of expected completion of specific 
AL doses (Table  4). Very similar results were observed 
to those for the same measurements after completion of 
the 3-day course. No significant effect of the intervention 
was observed on adherence to any of the five AL doses 
examined (Table 4) and no significant effect of the inter-
vention were observed on PP analysis (Additional file 2).
Patients’ return to health facility
Patients’ return to health facility was assessed by combin-
ing data in categories 1 and 2 for day 3 return and then 
by combined data across all categories for day 28 return 
(Table  5). Of 1032 patients in categories 1 and 2, 81.4% 
of patients (420/516) in the intervention group and 74.0% 
of patients (382/516) in the control group returned to the 
facility on day 3. Similarly, among 1677 patients sched-
uled to return on day 28, 63.4% (525/828) returned in the 
intervention group and 52.5% (446/849) returned in the 
control group. Receiving the SMS intervention signifi-
cantly increased odds of returning to the facility on day 3 
(OR = 1.55; 95% CI = 1.15–2.08; p = 0:004) and on day 
28 (OR = 1.58; 95% CI = 1.30–1.92; p < 0.001) (Table 5).
Adjustment for covariates
No covariate met the 5% inclusion criteria described 
above for either outcome of interest (Additional files 3 
and 4) and therefore only unadjusted effects of the inter-
vention are presented, as above. Furthermore, no covari-
ate showed statistically significant associations with 
outcome at p value of  <0.10 on ITT or on PP analysis 
(Additional files 3 and 4).
Discussion
This randomized controlled trial in western Kenya 
showed that SMS reminders significantly increased the 
rates of return to the health facility following anti-malar-
ial treatment but did not have any effect on adherence to 
AL medications. The results of this efficacy trial compar-
ing an SMS intervention to optimum clinical practices 
have several important implications.
Nearly all children completed all AL doses in this trial, 
which indicates substantially higher adherence than pre-
viously observed in evaluations conducted under the rou-
tine conditions in the same area [32, 33], in other parts 
of Kenya [39], and across Africa [40–45]. The high avail-
ability of AL blister packs during home visits and the 
evidence of empty packs provided confidence of high 
completion rates. Timely completion of all AL doses was 
lower (71%), but still substantially higher than reported 
in many previous studies [23, 40–42]. Adherence results 
for individual doses measured by home visits conducted 
closer to the expected time of administration were simi-
lar with measurements three days after the treatment. 
This suggests that self-reporting was unlikely to have 
introduced recall bias. While non-completion of AL 
doses compromises treatment outcome and contributes 
to the development of resistance [25, 46, 47] it is unclear 
how strictly dose intervals must be adhered to in order 
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to avoid adverse consequences and this trial was not 
designed to examine this.
Two other previous effectiveness trials tested effects 
of innovative SMS reminders on patients’ adherence to 
anti-malarials and these showed discordant results, but 
lower overall adherence [22, 23]. Due to methodologi-
cal differences where different modalities of SMS inter-
ventions were used in different settings, comparisons 
between studies are problematic. Under the trial condi-
tions reported here, SMS reminders were unnecessary 
as adherence levels were already high. It is possible that 
the excluded patients from the trial were those in whom 
poor adherence was most likely. This can only be a partial 
explanation for high adherence rates, since relatively few 
caregivers were excluded simply because they declined to 
take part or lacked access to SMS reminders (most exclu-
sions were for children without malaria).
A recent review of anti-malarial adherence studies 
suggests that interactions between research teams or 
medical staff and patients is likely to influence adherence 
levels [19]. Specifically, the conduct of consultations by 
research staff, parasitological confirmation, consenting 
of patients prior to the treatment, awareness of partici-
pants about home visits, dispenser’s observation of the 
swallowing of the first dose, may all have contributed to 
higher adherence levels in this trial. The importance of 
Table 2 The characteristics of the study subjects by arm and category

















n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%)
Child characteristics
 Age (months)
  < 12 25 (9.8) 20 (7.7) 25 (9.5) 26 (10.1) 29 (8.7) 36 (11.5) 79 (9.3) 82 (9.9)
  12–59 225 (88.6) 237 (91.5) 234 (89.3) 229 (89.1) 300 (90.1) 270 (86.6) 759 (89.4) 736 (88.9)
  60 4 (1.6) 2 (0.8) 3 (1.2) 2 (0.8) 4 (1.2) 6 (1.9) 11 (1.3) 10 (1.2)
 Male gender 143 (56.3) 144 (55.6) 136 (51.9) 129 (50.2) 175 (52.6) 163 (52.2) 454 (53.5) 436 (52.7)
 Weight (kg)
  < 15 179 (70.5) 177 (68.3) 186 (71.0) 192 (74.7) 230 (69.1) 243 (77.9) 595 (70.1) 612 (73.9)
  15–24 75 (29.5) 82 (31.7) 76 (29.0) 64 (24.9) 103 (30.9) 69 (22.1) 254 (29.9) 215 (26.0)
  ≥ 25 0 0 0 1 (0.4) 0 0 0 1 (0.1)
Temperature ≥37.5 °C 172 (67.7) 178 (68.7) 173 (66.0) 177 (68.9) 242 (72.7) 231 (74.0) 587 (69.1) 586 (70.8)
Parasite density >10,000/
µl
188 (74.0) 197 (76.1) 196 (74.8) 187 (72.8) 263 (79.0) 224 (71.8) 647 (76.2) 608 (73.4)
Caregiver characteristics
 Age (years)
  ≤20 41 (16.1) 62 (23.9) 54 (20.6) 57 (22.2) 56 (16.8) 63 (20.2) 151 (17.8) 182 (22.0)
  20–40 years 189 (74.4) 182 (70.3) 195 (74.4) 181 (70.4) 251 (75.4) 238 (76.3) 635 (74.8) 601 (72.5)
  >40 16 (6.3) 12 (4.6) 7 (2.7) 12 (4.7) 15 (4.5) 8 (2.6) 38 (4.5) 32 (3.9)
  Missing age 8 (3.2) 3 (1.2) 6 (2.3) 7 (2.7) 11 (3.3) 3 (0.9) 25 (2.9) 13 (1.6)
 Female gender 238 (93.7) 241 (93.1) 245 (93.5) 246 (95.7) 321 (96.4) 298 (95.5) 804 (94.7) 785 (94.8)
 Relationship to the child
  Mother 225 (88.6) 224 (86.5) 242 (92.4) 233 (90.7) 292 (87.7) 292 (93.6) 759 (89.4) 749 (90.5)
  Father 15 (5.9) 13 (5.0) 10 (3.8) 10 (3.9) 13 (3.9) 12 (3.9) 38 (4.5) 35 (4.2)
  Other 14 (5.5) 22 (8.5) 10 (3.8) 14 (5.4) 28 (8.4) 8 (2.5) 52 (6.1) 44 (5.3)
 Educational level
  No formal education 3 (1.2) 11 (4.3) 8 (3.0) 8 (3.1) 9 (2.7) 10 (3.2) 20 (2.4) 29 (3.5)
  Primary 153 (60.2) 160 (61.8) 163 (62.2) 165 (64.2) 211 (63.4) 198 (63.5) 527 (62.0) 523 (63.2)
  Secondary and above 97 (38.2) 87 (33.6) 88 (33.6) 84 (32.7) 111 (33.3) 104 (33.3) 296 (34.9) 275 (33.2)
  Missing information 1 (0.4) 1 (0.3) 3 (1.2) 0 2 (0.6) 0 6 (0.7) 1 (0.1)
 Phone ownership status
  Personal 193 (76.0) 209 (80.7) 188 (71.8) 193 (75.1) 259 (77.8) 237 (76.0) 640 (75.4) 639 (77.2)
  Shared 61 (24.0) 50 (19.3) 74 (28.2) 64 (24.9) 74 (22.2) 75 (24.0) 209 (24.6) 189 (22.8)
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optimum clinical practices, including appropriate drug 
dispensing and counselling according to standard guide-
lines, either provided under the trial or routine condi-
tions, seems to be a factor for adherence [48]. Under ‘real 
world’ conditions SMS reminders may lead to improved 
adherence to anti-malarial medicines [22]. However it 
can be argued that ‘real world’ conditions can be altered 
by the implementation of policy. For instance, healthcare 
providers in routine settings could provide explanations 
and demonstrate the illustrated instructions on blis-
ter packs as done in this trial. The investment required 
for SMS reminder systems should be compared against 
Table 3 Effects of  the intervention on  AL adherence measured the day after  expected completion of  the full 3-day 










OR (95% CI) p value
All AL doses completed 282 (97.6) 267 (97.8) 549 (97.7) 1.10 (0.37–3.33) 0.860
All doses timely completed 209 (72.3) 189 (69.2) 398 (70.8) 0.82 (0.56–1.19) 0.302
Dose 2
 Adherent 222 (76.8) 205 (75.1) 427 (76.0) 0.87 (0.58–1.29) 0.479
Dose 3
 Adherent 274 (94.8) 267 (97.8) 541 (96.3) 2.44 (0.93–6.37) 0.070
Dose 4
 Adherent 271 (93.8) 262 (96.0) 533 (94.8) 1.58 (0.73–3.41) 0.242
Dose 5
 Adherent 273 (94.5) 264 (96.7) 537 (95.6) 1.72 (0.75–3.96) 0.203
Dose 6
 Adherent 256 (88.6) 249 (91.2) 505 (89.9) 1.30 (0.74–2.28) 0.355
Table 4 Effects of the intervention on adherence to  individual AL doses measured within 24 h of expected completion 
of the specific dose—ITT analysis by category






OR (95% CI) p value
Dose 2 1 N = 237 N = 241 n = 478
 Adherent 192 (81.0) 186 (77.2) 378 (79.1) 0.76 (0.48–1.19) 0.233
Dose 3 1
 Adherent 230 (97.1) 235 (97.5) 465 (97.3) 1.19 (0.39–3.59) 0.762
Dose 4 2 N = 226 N = 239 N = 465
 Adherent 205 (90.7) 223 (93.3) 428 (92.0) 1.43 (0.73–2.81) 0.303
Dose 5 2
 Adherent 207 (91.6) 220 (92.1) 427 (91.8) 1.06 (0.55–2.06) 0.857
Dose 6 3 N = 289 N = 273 N = 562
 Adherent 256 (88.6) 249 (91.2) 505 (89.9) 1.30 (0.74–2.28) 0.355







OR (95% CI) p value
Day 3 return N = 516 N = 516 N = 1032
(Patients from category 1 and 2) 382 (74.0) 420 (81.4) 802 (77.7) 1.55 (1.15–2.08) 0.004
Day 28 return N = 849 N = 828 N = 1677
(Patients from all categories) 446 (52.5) 525 (63.4) 971 (57.9) 1.58 (1.30–1.92) <0.001
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investment in the basic essentials and interventions 
to improve provider adherence to national treatment 
guidelines.
In contrast to the findings on adherence, SMS remind-
ers increased the rates of patients returning to health 
facilities for routine follow-up. Increasing the day 3 
return from 74 to 81% and the day 28 return from 53 
to 63% is a relatively modest but still significant impact 
on behaviour. Two trials in Kenya have shown similar 
effects of SMS on postpartum [11] and postoperative [12] 
attendance, as well as a larger 18% effect on attendance 
for follow-up HIV testing [13]. Post-treatment attend-
ances among patients not receiving SMS reminders were 
significantly higher than the range 12–41% observed in 
Kenyan appointment trials, as well as higher than the 
44% of sick children returning to health facility follow-
ing outpatient counselling in Sudan [21]. In the Ken-
yan trial reported in this manuscript, day 28 returns 
are likely to have been positively influenced by financial 
transport compensations and day 3 returns are likely to 
have been influenced by home visits. Nevertheless, the 
SMS reminder was seen to be significant in improving 
returns at both day 3 and day 28 despite this background. 
The costs and benefits of improved day 3 post-treatment 
returns among children receiving SMS reminders should 
be considered for routine use, particularly given the 
importance of pragmatic, artemisinin resistance moni-
toring [29, 30].
Conclusions
When optimum care under the trial conditions is pro-
vided, text-message reminders can increase a child’s 
return to the health facility following anti-malarial treat-
ment, without an additional effect on already high levels 
of AL adherence that occur under trial conditions. Fur-
ther effectiveness studies under varying real world con-
ditions in different settings are needed to determine the 
optimum role of text-message reminders in improving 
patients’ adherence to anti-malarial medicines.
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